- Die vier harmonischen Tiere: Ein Kommentar zum ersten Kapitel aus „Grundlegendes zu einer Erweiterung der Heilkunst“
Der Merkurstab, März/April 2026 - Development of a Performance Measurement Framework for European Health Technology Assessment: Stakeholder-Centric Key Performance Indicators Identified in a Delphi Approach by the European Access Academy
Journal of Market Access & Health Policy, January 2026 - Die Clavicula: Ein ganz besonderer "Schlüssel"
Der Merkurstab, November/Dezember 2025 - The ‘Comedy of Errors’: Putting the principles of ‘false positive’ and ‘false negative’ error into context
Der Merkurstab, May/June 2025 - Development and Pilot Test of the Registry Evaluation and Quality Standards Tool: An Information Technology–Based Tool to Support and Review Registries
Value in Health, March 2022 - Intraindividual Comparisons to Determine Comparative Effectiveness: Their Relevance for G-BA’s Health Technology Assessments
Value in Health, May 2021 - Review of Relative effectiveness assessments (REAs) of pharmaceuticals at the European network for health technology assessment (EUnetHTA): A first step towards a consolidated European perspective on comparative effectiveness & safety?
Health Policy, June 2020 - Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree
Health Economics Review, December 2019 - Analysis of acceptance rate and rationales for rejection of indirect comparisons in IQWiGʼs benefit assessments
Gesundheitsökonomie & Qualitätsmanagement, May 2019 - Effect of crossover in oncology clinical trials on evidence levels in early benefit assessment in Germany
Value in Health, June 2018 - Is the EUnetHTA HTA core model fit for purpose? Evaluation from an industry perspective
International Journal of Technology Assessment in Health Care, October 2018 - Leveraging EUnetHTA’s conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer’s point of view
Health Economics Review, September 2018 - “Market withdrawals” of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendation
Health Economics Review, September 2018 - Are FJC appraisals suitable to guide therapeutic decisions?
Gesundhheitsökonomie & Qualitätsmanagement, September 2018 - Different approaches to evidence-based medicine in regulatory, health technology, and clinical decision making
Pharmaceutical Medicine, July 2017 - Formative biology of bee swarms
Tycho de Brahe Year Book, November 2016 - Aristotelian cause – Effect principles in medicine
Der Merkurstab, April 2016 - Comparing EMA post authorization measures and additional evidence requirements by HTA bodies
Health Economics Review, November 2016 - Patient relevance of primary endpoints across various disease areas
BMC Health Services Research, November 2016 - Early benefit assessments in oncology in Germany: How can a clinically relevant endpoint not be relevant to patients?
Drugs in R&D, August 2015 - Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation
European Journal of Health Economics, July 2014 - Questioning patient subgroups for benefit assessment: challenging the German Gemeinsamer Bundesausschuss approach
Value in Health, June 2014 - Content comparison of QoL instruments in COPD
Respiratory Medicine, January 2007 - Direct costs in rheumatoid arthritis
Annals of Rheumatic Diseases, March 2005 - ICF core sets for diabetes mellitus
Journal of Rehabilitative Medicine, August 2004 - ICF core sets for obesity
Journal of Rehabilitation Medicine, August 2004
 | Contact us for more information: info@r-connect.org |
